

Schizophrenia

A Study to Assess the Effects of RO6889450 in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Trial Status
Terminated

Trial Runs In
4 Countries

Trial Identifier
NCT03669640 2020-004752-16
BP40283

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03669640 2020-004752-16 BP40283
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years & ≤ 55 Years

Healthy Volunteers
No
